Growth hormone support peptides Sermorelin, Ipamorelin, and CJC-1295 stimulate the pituitary gland to release the body's own growth hormone
Do not use if the solution is not clear
Disclosure of interest: Nothing to disclose Poster Session I - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P262 - ESOC25-1312 DISCHARGE RATES TO HOME FOLLOWING RECURRENT ISCHEMIC STROKE (IS): A REAL-WORLD DATA ANALYSIS ON THE CURRENT PATIENT JOURNEY IN THE US Mark Alberts 1 , Jenny Jiang 2 , Yan Wang 3 , Arimanda Reddy 4 , Haitham Alabsi 5 , Meg Thompson 5 , Merena Henderson 2 , Xiaoyan Li 2 , Priyanka Gaitonde 2 1 Hartford HealthCare, Hartford, United States, 2 Bristol Myers Squibb, Lawrenceville, United States, 3 Analysis Group Inc., Los Angeles, United States, 4 Mu-Sigma, Chicago, United States, 5 Johnson & Johnson, Raritan, United States Background and Aims: A significant proportion of IS patients experience recurrent IS within five years
There are no Therapeutic Use Exemptions (TUEs) for BPC-157, and its presence in an athletes system can lead to disqualification
The majority of the published data is still preclinical, and there are still plenty of issues concerning the safety, pharmacology and effectiveness of the use of BPC-157 to be answered
Frontiers in Pharmacology , 12, 627533
